Clinical Studies
Review the detailed clinical trial results for NeuralCIM treatment, including study design, participant outcomes, and statistical significance.
Phase III Clinical Trial Results
NeuralCIM has undergone rigorous clinical testing, demonstrating significant efficacy in treating mild-to-moderate Alzheimer's disease with an excellent safety profile.
174
Total Participants Enrolled
170
Participants Treated
85%
Trial Completion Rate
Study Design
NeuroEPO + 0.5 mg
57
participants
NeuroEPO + 1.0 mg
56
participants
Placebo Group
57
participants
Mean age 74.0 years; 121 (71.2%) women
48 weeks with long-term follow-up
Primary Outcomes: ADAS-Cog11 Scores
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) is the gold standard for measuring cognitive function in clinical trials. Lower scores indicate better cognitive performance.
NeuroEPO + 0.5 mg
-3.0
Median change at 48 weeks
95% CI: -4.3 to -1.7
NeuroEPO + 1.0 mg
-4.0
Median change at 48 weeks
95% CI: -5.9 to -2.1
Placebo
+4.0
Median change at 48 weeks
95% CI: 1.9 to 6.1
0.5 mg vs Placebo
7.0 points
95% CI: 4.5-9.5, P equals 0.000
1.0 mg vs Placebo
8.0 points
95% CI: 5.2-10.8, P equals 0.000
Statistically Significant Improvement
Both treatment groups showed highly significant cognitive improvement compared to placebo (P = 0.000), representing a major breakthrough in Alzheimer's treatment.
Secondary Outcomes
NeuralCIM demonstrated statistically significant improvement across multiple clinical measures.
CIBIC+
Clinician's Interview-Based Impression of Change showed significant improvement
MoCA
Montreal Cognitive Assessment demonstrated significant improvement
GDS
Geriatric Depression Scale showed positive outcomes
NPI
Neuropsychiatric Inventory demonstrated improvement
Brain Perfusion
Imaging studies showed improved blood flow to key brain regions affected by Alzheimer's disease
Long-Term Follow-Up Results
The most remarkable finding came from long-term follow-up of patients who continued NeuralCIM treatment beyond the initial 48-week study period.
Disease Stabilization
Patients who continued treatment for two years stabilized their disease, halting the typical progression of Alzheimer's.
Control Group Decline
Subjects who did not continue treatment showed the cognitive impairment characteristic of disease progression.
Treatment vs. Placebo Trajectory
Cognitive function maintained at 2 years
Typical Alzheimer's progression observed
"The difference between continued treatment and discontinuation was stark—offering hope for long-term disease management."
Safety Profile
NeuralCIM demonstrated excellent safety throughout clinical trials.
No Serious Adverse Events
Clinical studies reported no serious adverse events related to NeuralCIM treatment. The treatment demonstrated a very good safety profile throughout the trial period.
Well Tolerated
No Hematopoietic Effects
Continuous Monitoring
Regulatory Approval
NeuralCIM has received accelerated approval from the Cuban Regulatory Authority (CECMED) as a treatment for mild-moderate Alzheimer's disease.
CECMED
Cuban Regulatory Authority
Accelerated Approval
Ready to Learn More?
Contact us to discuss how NeuralCIM clinical results may apply to your loved one's situation.